邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

自体造血干细胞移植是适合移植的多发性骨髓瘤患者的标准治疗?

陈文明

downloadPDF
文章导航 > 协和医学杂志  > 2018 >  9(3): 224-227
陈文明. 自体造血干细胞移植是适合移植的多发性骨髓瘤患者的标准治疗?[J]. 协和医学杂志, 2018, 9(3): 224-227. doi: 10.3969/j.issn.1674-9081.2018.03.007
引用本文: 陈文明. 自体造血干细胞移植是适合移植的多发性骨髓瘤患者的标准治疗?[J]. 协和医学杂志, 2018, 9(3): 224-227. doi: 10.3969/j.issn.1674-9081.2018.03.007
shu
Wen-ming CHEN. Is Autologous Stem Cell Transplantation the Standard Treatment for Transplant-eligible Patients with Multiple Myeloma?[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 224-227. doi: 10.3969/j.issn.1674-9081.2018.03.007
Citation: Wen-ming CHEN. Is Autologous Stem Cell Transplantation the Standard Treatment for Transplant-eligible Patients with Multiple Myeloma?[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 224-227. doi: 10.3969/j.issn.1674-9081.2018.03.007
shu

自体造血干细胞移植是适合移植的多发性骨髓瘤患者的标准治疗?

doi: 10.3969/j.issn.1674-9081.2018.03.007

  • 首都医科大学附属北京朝阳医院血液科, 北京 100020

详细信息
    作者简介:

    陈文明：电话:010-85231000, E-mail:13910107759@qq.com

  • 中图分类号: R733.3

Is Autologous Stem Cell Transplantation the Standard Treatment for Transplant-eligible Patients with Multiple Myeloma?

  • Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

More Information

    摘要
  • 摘要: 自体造血干细胞移植(autologous stem cell transplantation, ASCT)是多发性骨髓瘤的标准治疗策略之一。不论是传统药物时代, 还是新药时代, ASCT均作为多发性骨髓瘤治疗的重要手段之一。尽管文献报道ASCT可延长患者的无进展生存期, 但对总生存期的获益有待进一步探讨, 特别是高危患者, ASCT可能并不能使患者获益。此外, ASCT后的巩固、维持治疗对预后也至关重要, 且ASCT具有存在相关不良反应以及再发肿瘤的风险, 故ASCT用于多发性骨髓瘤治疗的价值仍有待商榷。
    Abstract: Autologous stem cell transplantation(ASCT) is a standard choice for the treatment of multiple myeloma (MM). ASCT is an important therapy for MM not only in the era of classical drugs but also in the times of new medicines. As literature reported, the length of progression-free survival of MM patients can be extended by ASCT. But the effect of ASCT on the overall survival is still unknown, especially for high-risk patients with cytogenetic abnormalities. Consolidation and maintenance after the ASCT is very important to maintain the effects of ASCT. It is necessary to be aware of the side effects and second primary malignances after ASCT.
    • HTML全文
    • 参考文献(23)
  • [1] Blokhin N, Larionov L, Perevodchikova N, et al.[Clinical experiences with sarcolysin in neoplastic diseases] [J]. Ann N Y Acad Sci, 1958, 68:1128-1132. doi:  10.1111/j.1749-6632.1958.tb42675.x
    [2] McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma[J]. Lancet, 1983, 2:822-824. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=6137651
    [3] Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. N Engl J Med, 1999, 341:1565-1571. doi:  10.1056/NEJM199911183412102
    [4] Orlowski RZ, Eswara JR, Lafond-Walker A, et al.Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor[J]. Cancer Res, 1998, 58:4342-4348. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM9766662
    [5] Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies[J]. J Clin Oncol, 2002, 20:4420-4427. doi:  10.1200/JCO.2002.01.133
    [6] Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells[J]. Cancer Res, 2001, 61:3071-3076. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM11306489
    [7] Kumar SK, Callander NS, Alsina M, et al. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15:230-269. doi:  10.6004/jnccn.2017.0023
    [8] Moreau P, San Miguel J, Sonneveld P, et al.Multiple myeloma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28:iv52-iv61. http://annonc.oxfordjournals.org/content/21/suppl_5/v155.full
    [9] Chng WJ, Dispenzieri A, Chim CS, et al.IMWG consensus on risk stratification in multiple myeloma[J]. Leukemia, 2014, 28:269-277. doi:  10.1038/leu.2013.247
    [10] Dingli D, Ailawadhi S, Bergsagel PL, et al. Therapy for relapsed multiple myeloma:guidelines from the mayo stratification for myeloma and risk-adapted therapy[J]. Mayo Clin Proc, 2017, 92:578-598. doi:  10.1016/j.mayocp.2017.01.003
    [11] Barlogie B, Attal M, Crowley J, et al.Long-term follow-up of autotransplantation trials for multiple myeloma:update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences[J]. J Clin Oncol, 2010, 28:1209-1214. doi:  10.1200/JCO.2009.25.6081
    [12] Porcher R, Lévy V, Fermand JP, et al. Evaluating high dose therapy in multiple myeloma:use of quality-adjusted survival analysis[J]. Qual Life Res, 2002, 11:91-99. doi:  10.1023/A:1015096313594
    [13] Facon T, Mary JY, Harousseau JL, et al. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM)protocol[J]. Blood, 1996, 88:2729.
    [14] Child JA, Morgan GJ, Davies FE, et al.High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma[J]. N Engl J Med, 2003, 348:1875-1883. doi:  10.1056/NEJMoa022340
    [15] Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma:final results of phase Ⅲ US intergroup trial S9321[J]. J J Clin Oncol, 2006, 24:929-936. doi:  10.1200/JCO.2005.04.5807
    [16] Rosiñol L, Pérez-Simón JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma[J]. Blood, 2008, 112:3591-3593. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=e3c0b876e7fe028ba2e016172004035e
    [17] Lokhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma:a prospective evaluation of patients treated in the phase Ⅲ study HOVON 24 MM[J]. J Clin Oncol, 2003, 21:1728-1733. doi:  10.1200/JCO.2003.04.033
    [18] Palumbo A, Bringhen S, Petrucci MT, et al.Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70:results of a randomized controlled trial[J]. Blood, 2004, 104:3052-3057. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM15265788
    [19] Facon T, Mary JY, Hulin C, et al.Melphalan and predni-sone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06):a randomised trial[J]. Lancet, 2007, 370:1209-1218. doi:  10.1016/S0140-6736(07)61537-2
    [20] Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma:a systematic review and meta-analysis of randomized controlled trials[J]. Biol Blood Marrow Transplant, 2007, 13:183-196. doi:  10.1016/j.bbmt.2006.09.010
    [21] Etto LY, Morelli VM, Silva VC, et al. Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients[J]. Clinics (Sao Paulo), 2011, 66:1855-1859. http://europepmc.org/articles/PMC3203955/
    [22] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma[J]. N Engl J Med, 2017, 376:1311-1320. doi:  10.1056/NEJMoa1611750
    [23] Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma[J]. Blood, 2012, 120:1067-1076. doi:  10.1182/blood-2012-01-405985
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  232
  • HTML全文浏览量:  25
  • PDF下载量:  201
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-07-25
  • 刊出日期:  2018-05-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！